Gross Margin % is calculated as gross profit divided by its revenue. Biodesix's Gross Profit for the
three
months ended in Dec. 2023 was $11.29 Mil. Biodesix's Revenue for the
three
months ended in Dec. 2023 was $14.67 Mil. Therefore, Biodesix's Gross Margin % for the quarter that ended in Dec. 2023 was 77.00%.
Warning Sign:
Biodesix Inc gross margin has been in long-term decline. The average rate of decline per year is -2.9%.
The historical rank and industry rank for Biodesix's Gross Margin % or its related term are showing as below:
BDSX'
s Gross Margin % Range Over the Past 10 Years
Min: 44.01 Med: 68.23 Max: 78.44
Current: 73.5
During the past 6 years, the highestGross Margin % of Biodesix was 78.44%. The lowest was 44.01%. And the median was 68.23%.
BDSX's Gross Margin % is ranked better than 82.24% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 45.595
vs BDSX: 73.50
Biodesix had a gross margin of 77.00% for the quarter that ended in Dec. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Biodesix was -2.90% per year.
Biodesix Gross Margin % Historical Data
The historical data trend for Biodesix's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biodesix's Gross Margin %
For the Diagnostics & Research subindustry, Biodesix's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biodesix's Gross Margin % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Biodesix's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Biodesix (NAS:BDSX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Biodesix had a gross margin of 77.00% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Biodesix Gross Margin % Related Terms
Thank you for viewing the detailed overview of Biodesix's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BDSX has been successfully added to your 